人血高密度脂蛋白治疗冠心病的疗效观察  

Curative Effect of Clinical Application of Human Blood High Density Lipoprotein to the Treatment of Coronary Arterial Sclerosis

作　　者：张兴义[1] 赵洁[1] 高云峰[2] 于家禄[2] 张树荣 隋淑华 王文厚 

机构地区：[1]卫生部长春生物制品研究所,长春130062 [2]中国人民解放军二○八医院,长春130062 [3]中国人民解放军二○六医院

出　　处：《中国生物制品学杂志》1992年第4期184-188,共5页Chinese Journal of Biologicals

摘　　要：应用人血高密度脂蛋白治疗冠心病患者52例,按1974年及1979年全国冠心病普查和预防座谈会上制订的疗效判定标准,总有效率为100％。治疗后胸闷,气短,乏力症状消失,心慌有了明显改善。心绞痛消失或改善者为100％。心电图恢复或改善者为90.4％,而用硝酸酯和硝苯吡啶常规治疗的对照组,心绞痛和心电图改善者分别为66.6％和50％,HDL明显优于常规药物。应用HDL治疗后心功能和超声心动图有了变化,ICT/LVET和左室舒末内径明显缩小,心功能和超声心动图改善分别为76.92％和57.84％。血脂浓度降低显著,总胆固醇下降高达34.8～43.0％,甘油三酯下降17.0～21.4％。治疗52例,未见有任何副作用。52 patients suffered from coronary arterial sclerosis were treated with human blood high density lipoprotein (HDL). In a 3 months-course of treatment, 1044mg of HDL was administered intramuscularly. The overall effective rate was 100%. Symptoms of palpitation and short breath were disappeared and stuffy chest was significantly reduced. In all the patients, symptoms of angina was reduced or disappeared. The ECG of 90.4% of patients was returned to normal or improved. However, of the 42 patients treated with nitrate and nifedipine, the rate of improvement of angina and ECG were 66.6% and 50%, respectively. In the HDL treated group, the cardiac ability of 76.6% of patients and the echocardiography (UCG) of 57.84% of patients were improved. The concentration of blood lipid obviously dropped. The dropping ranges of the total level of cholesterol and triglyceride were 34.8～43.0% and 17.0～21.4%, respectively. The HDL did not cause any side effect and obviously superior to common medicines.

关 键 词：人血高密度脂蛋白 冠心病治疗 

分 类 号：R977[医药卫生—药品]